SunEdison Inc. (NYSE:SUNE) is set to report first-quarter 2014 results on May 8. Last quarter, the company posted a negative earnings surprise of 500.0%. Let’s see how things are shaping up for this announcement. Sunedison Inc (NYSE:SUNE) shares after opening at $20.24 moved to $20.89 on last trade day and at the end of the day closed at $ 19.84 . Company price to sales ratio in past twelve months was calculated as 2.64 and price to cash ratio as 9.25. Sunedison Inc (NYSE:SUNE) showed a positive weekly performance of 2.74%.
Hansen Medical, Inc. (NASDAQ:HNSN), a global leader in intravascular robotics, announced it will exhibit its Sensei® X Robotic Catheter System at the Heart Rhythm Society’s (HRS) Annual Scientific Sessions from May 7 – 10 at the Moscone Center in San Francisco, California. Hansen will also reveal its new Sensei X2 Robotic System, which features faster processing, enhanced image integration and a slimmer design. The Sensei X2 is not yet commercially available in the U.S. or Europe. The Company will be conducting product demonstrations and displaying the Sensei Robotic System at Booth 620. Hansen Medical, Inc. (NASDAQ:HNSN) shares fell -3.59% in last trading session and ended the day on $1.88. HNSN return on equity ratio is recorded as -477.10% and its return on assets is -96.70%. Hansen Medical, Inc. (NASDAQ:HNSN) yearly performance is -10.05%.
Alnylam Pharmaceuticals, Inc (NASDAQ:ALNY) a leading RNAi therapeutics company, announced that it is advancing its Development Candidate (DC) for ALN-AAT, an RNAi therapeutic targeting alpha-1 antitrypsin (AAT) in development for the treatment of AAT deficiency-associated liver disease. New pre-clinical data were presented in a Late-Breaking Abstract Session at Digestive Disease Week (DDW), held May 3 – 6, 2014 in Chicago, Illinois. ALN-AAT is one of Alnylam’s genetic medicine programs, which are RNAi therapeutics directed toward genetically defined targets for the treatment of diseases with high unmet medical need. AAT deficiency-associated liver disease is caused by accumulation of mutant AAT protein (“Z-allele” or “Z-AAT”) in liver tissue with subsequent liver injury, fibrosis, cirrhosis, and, in some cases, hepatocellular carcinoma.Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) shares moved down -3.81% in last trading session and was closed at $52.27 while trading in range of $51.69 – $54.23 – Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) year to date (YTD) performance is -18.71%.
First Solar Inc. (NASDAQ:FSLR) the largest U.S. solar manufacturer, reported net income that was more than double estimates, largely the result of revenue from a 139-megawatt power plant in California. About 65 percent of the company’s revenue comes from building and selling utility-scale solar farms. That strategy depends on signing new deals as it completes construction on projects that power companies have already agreed to buy. First Solar, Inc. (NASDAQ:FSLR) weekly performance is 1.77%. On last trading day company shares ended up $67.45. First Solar, Inc. (NASDAQ:FSLR) distance from 50-day simple moving average (SMA50) is 4.00%. Analysts mean target price for the company is $63.67.
Leave a Reply